Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Uterine Tubes01:16

Uterine Tubes

The uterine or fallopian tubes function as the conduit through which oocytes travel from the ovaries to the uterus. Each fallopian tube measures approximately 10 to 13 cm long and is anatomically divided into the infundibulum, ampulla, isthmus, and interstitial part (or intramural segment). The infundibulum is characterized by its funnel shape and features extensions called fimbriae which reach towards the peritoneal cavity. These fimbriae play a critical role during ovulation as they extend...
Uterus and Cervix01:18

Uterus and Cervix

The uterus, commonly called the womb, is a vital reproductive organ in females designed to provide a nurturing environment for the implantation and growth of an embryo. It is shaped like a hollow pear and positioned between the urinary bladder and the rectum. The uterus's structure allows it to support and protect a developing fetus throughout pregnancy.
The uterus is securely anchored within the pelvic cavity by paired broad ligaments on either side. It is further stabilized by three pairs of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Gynecologic oncology·2026
Same author

Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Endometriosis and ovarian cancer risk.

Gynecologic oncology·2026
Same author

An evaluation of avutometinib in combination with defactinib for <i>KRAS</i>-mutated recurrent low-grade serous ovarian cancer.

Expert review of anticancer therapy·2026
Same author

Hypofractionated short course radiation therapy for recurrent ovarian cancer.

Gynecologic oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Uterine sarcoma 2008.

Jeff F Lin1, Brian M Slomovitz

  • 1Women's Cancer Center, Morristown Memorial Hospital, 100 Madison Avenue, Morristown, NJ 07962, USA.

Current Oncology Reports
|October 22, 2008
PubMed
Summary
This summary is machine-generated.

Uterine sarcomas are rare, aggressive cancers. Surgery is the primary treatment, but adjuvant therapies offer limited survival benefits, necessitating clinical trial enrollment for rare cancer patients.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: Jun 28, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

  • Gynecologic Oncology
  • Soft Tissue Oncology
  • Rare Cancers

Background:

  • Uterine sarcomas are rare, aggressive soft tissue cancers with diverse histologic subtypes.
  • Common presentations include abnormal uterine bleeding or pelvic mass, often misdiagnosed as benign leiomyomas.
  • Major subtypes include carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma.

Purpose of the Study:

  • To provide an overview of uterine sarcomas, covering their nature, presentation, and management.
  • To highlight the challenges in evaluating adjuvant therapies due to rarity and aggressive nature.
  • To emphasize the importance of clinical trial participation for patients with uterine sarcomas.

Main Methods:

  • Review of existing literature on uterine sarcoma epidemiology, pathology, and treatment.
  • Analysis of current treatment modalities, including surgery and adjuvant therapies.
  • Discussion of challenges in clinical trial design and patient enrollment.

Main Results:

  • Surgery, primarily hysterectomy, is the cornerstone of uterine sarcoma treatment.
  • Adjuvant therapies (radiation, chemotherapy, hormonal therapy) show limited impact on overall survival.
  • Response rates and duration of response for metastatic or recurrent disease are often poor.

Conclusions:

  • Uterine sarcomas require a multidisciplinary approach, with surgery as the main intervention.
  • The rarity and aggressive behavior of these cancers limit the efficacy of adjuvant treatments and necessitate further research.
  • Enrollment in clinical trials is strongly recommended for patients with uterine sarcomas to advance treatment options.